

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF BRIDGING STUDY OF ASC18

The Board of Directors (the “**Board**”) of Ascletis Pharma Inc. (the “**Company**”) is pleased to announce that the Company has completed the bridging study of ASC18, which is the first one-pill, once-a-day fixed dose combination (FDC) as a complete Hepatitis C treatment developed by China-based biotech companies.

ASC18 FDC consists of 200 mg Ravidasvir (RDV) and 400 mg Sofosbuvir (SOF). The phase I bridging study of ASC18 was a randomized, two arms (i.e. ASC18 FDC tablet and (RDV 200 mg + SOF 400 mg given in separate pills)), two cycles, two phases (i.e. single dose phase and multiple dose phase), two-sequence crossover design. The results from the bridging study on 20 subjects indicated that ASC18 FDC tablet showed comparable pharmacokinetics (PK), safety and tolerability with RDV 200 mg + SOF 400 mg given in separate pills.

The STORM-C-1 phase II/III trial, conducted by Drugs for Neglected Diseases initiative (DNDi) and reported at the International Liver Conference held in Paris on April 12, 2018, enrolled 300 HCV patients administered with separate 200 mg RDV tablet plus 400 mg SOF tablet for 12 weeks for patients without liver cirrhosis and for 24 weeks for those with compensated cirrhosis. The results showed an overall cure rate (Sustained Virological Response, SVR12) of 97%, 96% in cirrhotic subjects, and high cure rates (SVR12) across the genotypes studied: 99% in Genotype 1a, 100% in Genotype 1b, 96% in Genotype 3a, 100% in Genotype 3b, and 81% among the small group of Genotype 6 subjects. The cure rates (SVR12) are high for people living with HCV/HIV using their usual treatment (97%) and people infected with Genotype 3 (97%) including those with cirrhosis (96%).

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately market ASC18 successfully.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People’s Republic of China
August 20, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.